Equity Research firms currently have a positive stance on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.80. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $19.75 on a short term basis.
At the time of writing, the stock was trading at $9.37. This represents a change from the opening price of -2.60%. In terms of performance, year to date, the stock is 41.67%. The monthly stock performance comes in at 4.16%. For the quarter, shares are performing at 3.82%. Weekly performance analysis shows the equity at 0.85%.
In taking a look at technical levels, shares are trading 1.19% away from the 50 day simple moving average and 9.70% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -19.85% away from it’s 52- week high and 108.22% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Inovio Pharmaceuticals, Inc.’s RSI stands at 48.89. In looking at volatility levels, the shares saw weekly volatility of 3.19% and 3.64% over the past month.